FindTrial
Sign In

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

A Phase 2b, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07589608
Enrollment
400
Registered
2026-05-15
Start date
2026-05-15
Completion date
2028-02-01
Last updated
2026-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight, Obesity

Brief summary

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.

Interventions

DRUGMacupatide

Administered SC

DRUGEloralintide

Administered SC

DRUGPlacebo

Administered SC

Sponsors

Eli Lilly and Company
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* See Master Protocol CWMM (NCT06143956) for inclusion criteria

Exclusion criteria

In addition to

Design outcomes

Primary

MeasureTime frame
Percent Change from Baseline in Body WeightBaseline, Week 36

Secondary

MeasureTime frame
Percent Change from Baseline in Body WeightBaseline, Week 48
Change from Baseline in Body WeightBaseline, Week 36
Percentage of Participants who Achieve ≥5% Body Weight ReductionWeek 36
Percentage of Participants who Achieve ≥10% Body Weight ReductionWeek 36
Change from Baseline in Body Mass Index (BMI)Baseline, Week 36

Countries

United States

Contacts

CONTACTTrial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
LillyTrials@Lilly.com317-615-4559
CONTACTPhysicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
STUDY_DIRECTORCall 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

Eli Lilly and Company

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 7, 2026